Author: Banimohamadâ€Shotorbani, Behnaz; Farajpour, Hekmat; Sefat, Farshid; Khosroshahi, Shiva Ahdi; Shafaei, Hajar; Heidari keshel, Saeed
Title: Efficacy of mesenchymal stromal cells and cellular products in improvement of symptoms for COVIDâ€19 and similar lung diseases Cord-id: 4zc1pwgs Document date: 2021_3_27
ID: 4zc1pwgs
Snippet: At the end of 2019, respiratory coronavirus diseases 2019 (COVIDâ€19) appeared and spread rapidly in the world. Besides several mutations, the outcome of this pandemic was the death up to 15% of hospitalized patients. Mesenchymal stromal cell therapy as a therapeutic strategy seemed successful in treatment of several diseases. Not only mesenchymal stromal cells of several tissues, but also their secreted extracellular vesicles and even secretome indicated beneficial therapeutic function. All of
Document: At the end of 2019, respiratory coronavirus diseases 2019 (COVIDâ€19) appeared and spread rapidly in the world. Besides several mutations, the outcome of this pandemic was the death up to 15% of hospitalized patients. Mesenchymal stromal cell therapy as a therapeutic strategy seemed successful in treatment of several diseases. Not only mesenchymal stromal cells of several tissues, but also their secreted extracellular vesicles and even secretome indicated beneficial therapeutic function. All of these three options were studied for treatment of COVIDâ€19 as well as those respiratory diseases that have similar symptom. Fortunately, most of the outcomes were promising and optimistic. In this paper, we review inâ€vivo and clinical studies which have been used different sources of mesenchymal stromal cell, secreted extracellular vesicles, and secretome to improve and treat symptoms of COVIDâ€19 and similar lung diseases.
Search related documents:
Co phrase search for related documents- acute ards respiratory distress syndrome and additional study: 1, 2, 3, 4, 5
- acute ards respiratory distress syndrome and adhesion molecule: 1, 2, 3, 4, 5, 6
- acute cardiac injury and additional study: 1
- acute inflammatory response and adaptive immune response: 1, 2, 3, 4
- acute lung damage and adaptive immune response: 1
- acute lung injury and adaptive immune response: 1, 2, 3, 4, 5
- acute lung injury and additional study: 1
- acute lung injury patient and additional study: 1
- acute phase and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8
- acute phase and additional study: 1, 2
Co phrase search for related documents, hyperlinks ordered by date